[go: up one dir, main page]

WO2009072267A1 - Ａｂｃｇ２阻害剤 - Google Patents

Ａｂｃｇ２阻害剤 Download PDF

Info

Publication number
WO2009072267A1
WO2009072267A1 PCT/JP2008/003557 JP2008003557W WO2009072267A1 WO 2009072267 A1 WO2009072267 A1 WO 2009072267A1 JP 2008003557 W JP2008003557 W JP 2008003557W WO 2009072267 A1 WO2009072267 A1 WO 2009072267A1
Authority
WO
WIPO (PCT)
Prior art keywords
abcg2
inhibitor
abcg2 inhibitor
disclosed
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2008/003557
Other languages
English (en)
French (fr)
Inventor
Ryuta Yamazaki
Hiroshi Hatano
Takashi Yaegashi
Yoshiaki Igarashi
Oh Yoshida
Yoshikazu Sugimoto
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yakult Honsha Co Ltd
Original Assignee
Yakult Honsha Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yakult Honsha Co Ltd filed Critical Yakult Honsha Co Ltd
Priority to EP08856722A priority Critical patent/EP2218719A4/en
Priority to US12/745,899 priority patent/US20100249089A1/en
Priority to JP2009544566A priority patent/JPWO2009072267A1/ja
Priority to CN2008801190824A priority patent/CN101883767A/zh
Priority to CA2707718A priority patent/CA2707718A1/en
Publication of WO2009072267A1 publication Critical patent/WO2009072267A1/ja
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

　本発明は乳がん耐性蛋白（ＢＣＲＰ／ＡＢＣＧ２）阻害剤に関する。 　一般式（１） ［式中、Ａは置換基を有してもよい３－８員の複素環を示す。］ で表されるアクリロニトリル誘導体又はその塩。
PCT/JP2008/003557 2007-12-03 2008-12-02 Ａｂｃｇ２阻害剤 Ceased WO2009072267A1 (ja)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP08856722A EP2218719A4 (en) 2007-12-03 2008-12-02 ABCG2 INHIBITORS
US12/745,899 US20100249089A1 (en) 2007-12-03 2008-12-02 Abcg2 inhibitor
JP2009544566A JPWO2009072267A1 (ja) 2007-12-03 2008-12-02 Ａｂｃｇ２阻害剤
CN2008801190824A CN101883767A (zh) 2007-12-03 2008-12-02 Abcg2抑制剂
CA2707718A CA2707718A1 (en) 2007-12-03 2008-12-02 Abcg2 inhibitor

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007312176 2007-12-03
JP2007-312176 2007-12-03

Publications (1)

Publication Number Publication Date
WO2009072267A1 true WO2009072267A1 (ja) 2009-06-11

Family

ID=40717449

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/003557 Ceased WO2009072267A1 (ja) 2007-12-03 2008-12-02 Ａｂｃｇ２阻害剤

Country Status (8)

Country Link
US (1) US20100249089A1 (ja)
EP (1) EP2218719A4 (ja)
JP (1) JPWO2009072267A1 (ja)
KR (1) KR20100100826A (ja)
CN (1) CN101883767A (ja)
CA (1) CA2707718A1 (ja)
TW (1) TW200927107A (ja)
WO (1) WO2009072267A1 (ja)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021215517A1 (ja) 2020-04-22 2021-10-28 ネオファーマジャパン株式会社 新型コロナウイルス感染症（ｃｏｖｉｄ－１９）の治療及び／又は予防剤

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3099156B1 (fr) * 2019-07-25 2022-01-28 Univ Grenoble Alpes Inhibiteurs selectifs du transporteur bcrp/abcg2 utilises comme agents pour abolir la resistance aux anticancereux

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004069233A1 (ja) 2003-02-04 2004-08-19 Kabushiki Kaisha Yakult Honsha 乳癌耐性蛋白阻害剤
WO2004069243A1 (ja) 2003-02-04 2004-08-19 Kabushiki Kaisha Yakult Honsha 乳癌耐性蛋白（ｂｃｒｐ）阻害剤
WO2006106778A1 (ja) 2005-03-30 2006-10-12 Kabushiki Kaisha Yakult Honsha Ｂｃｒｐ／ａｂｃｇ２阻害剤

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004069233A1 (ja) 2003-02-04 2004-08-19 Kabushiki Kaisha Yakult Honsha 乳癌耐性蛋白阻害剤
WO2004069243A1 (ja) 2003-02-04 2004-08-19 Kabushiki Kaisha Yakult Honsha 乳癌耐性蛋白（ｂｃｒｐ）阻害剤
WO2006106778A1 (ja) 2005-03-30 2006-10-12 Kabushiki Kaisha Yakult Honsha Ｂｃｒｐ／ａｂｃｇ２阻害剤

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
CANCER RES., vol. 59, 1999, pages 5938 - 5946
INT. J. CANCER, vol. 108, 2004, pages 146 - 151
J. CLIN. ONCOL., vol. 20, 2002, pages 2943 - 2950
MOL. CANCER THER., vol. 1, 2002, pages 417 - 425
MOL. CANCER THER., vol. 2, 2003, pages 105 - 112
PROC. NATL. ACAD. SCI. USA, vol. 95, 1998, pages 15665 - 15670
See also references of EP2218719A4

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021215517A1 (ja) 2020-04-22 2021-10-28 ネオファーマジャパン株式会社 新型コロナウイルス感染症（ｃｏｖｉｄ－１９）の治療及び／又は予防剤

Also Published As

Publication number Publication date
EP2218719A4 (en) 2012-01-11
CA2707718A1 (en) 2009-06-11
US20100249089A1 (en) 2010-09-30
CN101883767A (zh) 2010-11-10
TW200927107A (en) 2009-07-01
KR20100100826A (ko) 2010-09-15
JPWO2009072267A1 (ja) 2011-04-21
EP2218719A1 (en) 2010-08-18

Similar Documents

Publication Publication Date Title
DE602007014374D1 (de) Ä4,5'ü-bipyrimidinyl-6,4'-diaminderivate als proteinkinase-hemmer
ATE518860T1 (de) Pyrroloä2,3-büpyridinderivate als proteinkinaseinhibitoren
MX2008007823A (en) Merocyanine derivatives
DK1919907T5 (da) Heterocyklisk forbindelse
NL1030863A1 (nl) Heteroaromatische chinolineverbindingen.
IS8439A (is) Nýjar kínólín afleiður
ZA200606974B (en) Substituted 1,2,3,4-tetrahydrolsoquinoline derivatives
ATE481383T1 (de) 3-aza-bicycloä3.1.0ühexanderivate
DK1751131T3 (da) MTP-inhiberende arylpiperidiner eller -piperaziner, der er substitueret med 5-leddede heterocykler
IS8578A (is) 3- karbamoýl - 2- pýridón afleiður
ATE394399T1 (de) Tetrahydropyridoindolderivate
ATE540935T1 (de) Chinazolinderivate
ATE383361T1 (de) Pyrrazolopyrimidinderivate
EP1940843A4 (en) UNSATURATED HETEROCYCLIC DERIVATIVES
NL1031473A1 (nl) Cyclopentapyridine- en tetrahydrochinolinederivaten.
ATE417830T1 (de) Sulfonylbenzimidazolderivate
ATE500227T1 (de) Amidderivate
ATE487691T1 (de) Acetylenderivate
NL2000284A1 (nl) Pyrazine-derivaten.
WO2006039250A3 (en) Chemokine-binding heterocyclic compound salts, and methods of use thereof
EP1889848B8 (en) 6,7-unsaturated-7-carbamoyl substituted morphinan derivative
DE602006010581D1 (de) 4-phenyl-6-substituierte pyrimidin-2-carbonitrilderivate
ATE396724T1 (de) 1h-thieno 2,3-c-pyrazol-derivate als kinase-i- hemmer
ATE527255T1 (de) Aryl-isoxazol-4-yl-imidazol-derivate
NL2000336A1 (nl) Spirocyclische derivaten.

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880119082.4

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08856722

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2009544566

Country of ref document: JP

ENP Entry into the national phase

Ref document number: 20107011470

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2008856722

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2707718

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 12745899

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE